Eli Lilly EBITDA 2010-2023 | LLY
Eli Lilly annual and quarterly EBITDA history from 2010 to 2023. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Eli Lilly EBITDA for the quarter ending December 31, 2023 was $2.776B, a 25.51% increase year-over-year.
- Eli Lilly EBITDA for the twelve months ending December 31, 2023 was $7.985B, a 7.68% decline year-over-year.
- Eli Lilly 2023 annual EBITDA was $7.985B, a 7.68% decline from 2022.
- Eli Lilly 2022 annual EBITDA was $8.65B, a 9.43% increase from 2021.
- Eli Lilly 2021 annual EBITDA was $7.905B, a 7.08% increase from 2020.
Eli Lilly Annual EBITDA
(Millions of US $) |
| 2023 |
$7,985 |
| 2022 |
$8,650 |
| 2021 |
$7,905 |
| 2020 |
$7,382 |
| 2019 |
$6,207 |
| 2018 |
$5,144 |
| 2017 |
$3,571 |
| 2016 |
$4,758 |
| 2015 |
$4,117 |
| 2014 |
$4,039 |
| 2013 |
$6,816 |
| 2012 |
$6,196 |
| 2011 |
$6,902 |
| 2010 |
$7,858 |
| 2009 |
$6,885 |
Eli Lilly Quarterly EBITDA
(Millions of US $) |
| 2023-12-31 |
$2,776 |
| 2023-09-30 |
$861 |
| 2023-06-30 |
$2,492 |
| 2023-03-31 |
$1,856 |
| 2022-12-31 |
$2,211 |
| 2022-09-30 |
$2,039 |
| 2022-06-30 |
$1,559 |
| 2022-03-31 |
$2,840 |
| 2021-12-31 |
$2,363 |
| 2021-09-30 |
$2,264 |
| 2021-06-30 |
$1,773 |
| 2021-03-31 |
$1,506 |
| 2020-12-31 |
$2,360 |
| 2020-09-30 |
$1,637 |
| 2020-06-30 |
$1,521 |
| 2020-03-31 |
$1,864 |
| 2019-12-31 |
$1,741 |
| 2019-09-30 |
$1,719 |
| 2019-06-30 |
$1,746 |
| 2019-03-31 |
$1,002 |
| 2018-12-31 |
$1,246 |
| 2018-09-30 |
$1,759 |
| 2018-06-30 |
$420 |
| 2018-03-31 |
$1,719 |
| 2017-12-31 |
$691 |
| 2017-09-30 |
$915 |
| 2017-06-30 |
$1,596 |
| 2017-03-31 |
$370 |
| 2016-12-31 |
$1,023 |
| 2016-09-30 |
$1,336 |
| 2016-06-30 |
$1,297 |
| 2016-03-31 |
$1,101 |
| 2015-12-31 |
$671 |
| 2015-09-30 |
$1,320 |
| 2015-06-30 |
$1,244 |
| 2015-03-31 |
$883 |
| 2014-12-31 |
$648 |
| 2014-09-30 |
$941 |
| 2014-06-30 |
$1,235 |
| 2014-03-31 |
$1,215 |
| 2013-12-31 |
$1,230 |
| 2013-09-30 |
$1,894 |
| 2013-06-30 |
$1,867 |
| 2013-03-31 |
$1,825 |
| 2012-12-31 |
$1,356 |
| 2012-09-30 |
$1,509 |
| 2012-06-30 |
$1,564 |
| 2012-03-31 |
$1,767 |
| 2011-12-31 |
$1,311 |
| 2011-09-30 |
$1,944 |
| 2011-06-30 |
$1,945 |
| 2011-03-31 |
$1,702 |
| 2010-12-31 |
$1,674 |
| 2010-09-30 |
$2,097 |
| 2010-06-30 |
$2,128 |
| 2010-03-31 |
$1,959 |
| 2009-12-31 |
$926 |
| 2009-09-30 |
$1,996 |
| 2009-06-30 |
$1,903 |
| 2009-03-31 |
$2,060 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$695.710B |
$34.124B |
|
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
|
